An extended HR2 peptide achieved single-digit nanomolar inhibition of all major SARS-CoV-2 variants by blocking viral membrane fusion, without requiring chemical modifications like lipidation or stapling.
~100x more potentThe extended HR2 peptide is approximately 100-fold more potent than all previously published short, unmodified HR2 peptides — achieved simply by including an N-terminal extension
What the researchers found
Structural studies of the SARS-CoV-2 spike protein HR1HR2 six-helix bundle revealed an extended, well-folded N-terminal region of HR2 that interacts with the HR1 triple helix. Based on this structure:
- An extended HR2 peptide was designed that achieves single-digit nanomolar inhibition in cell-based fusion assays, VSV-SARS-CoV-2 chimera assays, and authentic SARS-CoV-2 infection assays
- No chemical modifications (lipidation, stapling) were needed
- The peptide inhibited all major SARS-CoV-2 variants tested
- ~100-fold more potent than all previously published short, unmodified HR2 peptides
- Very long inhibition lifetime after washout, suggesting it targets a pre-hairpin intermediate state of the spike protein
- The N-terminal extension beyond the HR2 helical region proved critical for potency
Why it matters
Monoclonal antibody therapies for COVID-19 became useless against Omicron and subsequent variants because they target the rapidly mutating receptor binding domain. This peptide targets the fusion machinery, which is far more conserved because mutations there can prevent the virus from entering cells at all. A simple, unmodified peptide that works against all variants and is cheap to manufacture could be an important addition to the antiviral toolkit — especially for future coronavirus outbreaks.
How the study worked
Structural biology (likely X-ray crystallography or cryo-EM) was used to characterize the HR1HR2 six-helix bundle of the SARS-CoV-2 spike protein. Based on the structure, an extended HR2 peptide was designed. Antiviral potency was tested in three assay systems: cell-based membrane fusion assays, VSV-SARS-CoV-2 chimeric virus assays, and authentic SARS-CoV-2 infection assays. Activity was assessed against multiple SARS-CoV-2 variants. Washout experiments tested the duration of inhibition to probe the mechanism of action.
What this study cannot tell us
This is a preprint (bioRxiv) that has not completed peer review at the time of cataloging. All data is in vitro — no animal or human studies are reported. The peptide's pharmacokinetic properties (stability in blood, half-life, tissue distribution) are not addressed. Route of administration for therapeutic use is unclear — peptides typically require injection. Manufacturing scalability, while theoretically simpler without modifications, still needs validation. In vivo efficacy may differ from cell-based assays.
How to read the evidence
This is a preprint describing in vitro work with multiple validated assay systems (cell fusion, chimeric virus, authentic virus). The structural basis, broad variant coverage, and 100-fold potency improvement are compelling. However, as a preprint without in vivo data, the evidence is at the early preclinical stage.
When this study was published
Posted as a preprint in 2022, this study addressed the urgent need for variant-resistant SARS-CoV-2 therapeutics. The fusion inhibitor concept remains relevant for coronavirus preparedness regardless of the current pandemic status.
The bigger picture
Peptide fusion inhibitors have a proven track record — enfuvirtide (Fuzeon) was the first FDA-approved peptide antiviral, blocking HIV membrane fusion by a similar mechanism. This SARS-CoV-2 peptide represents a next-generation approach: achieving exceptional potency without the chemical modifications typically needed to stabilize peptides. The concept of targeting conserved viral fusion machinery could be applied to other coronaviruses and envelope viruses, potentially providing broad-spectrum antiviral peptides for pandemic preparedness.
Questions still open
- Could this peptide be formulated as an inhaled nasal spray to block SARS-CoV-2 at the site of entry in the respiratory tract?
- Will the fusion machinery remain conserved enough across future SARS-CoV-2 variants and other coronaviruses to maintain this peptide's broad activity?
- Can the same structural approach — extending peptide inhibitors beyond the minimal helical domain — improve fusion inhibitors for other viruses like HIV, influenza, or RSV?
Common questions
How does this peptide stop the virus from infecting cells?
Why is this approach better than antibody treatments against COVID-19?
Read the original research
Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein.
bioRxiv : the preprint server for biology
Citation
Yang, Kailu; Wang, Chuchu; Kreutzberger, Alex J B; Ojha, Ravi; Kuivanen, Suvi; Couoh-Cardel, Sergio; Muratcioglu, Serena; Eisen, Timothy J; White, K Ian; Held, Richard G; Subramanian, Subu; Marcus, Kendra; Pfuetzner, Richard A; Esquivies, Luis; Doyle, Catherine A; Kuriyan, John; Vapalahti, Olli; Balistreri, Giuseppe; Kirchhausen, Tomas; Brunger, Axel T. (2022). Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2022.08.11.503553